Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IGF1R | P08069 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | HTR1A | P08908 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | THPO | P40225 | 1/20 | 0.45 |
| ▸ | MTOR | P42345 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | DHFR | P00374 | 2/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL7323720 | 0.82 | HTR1A (0.53) | MAPTALDH1A1SMN1; SMN2MAPK1HTR1A | |
| SCHEMBL11284379 | 0.74 | IGF1R (0.60) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL7318524 | 0.73 | HTR1A (0.62) | MAPTALDH1A1SMN1; SMN2MAPK1HTR1A | |
| SCHEMBL4037828 | 0.72 | IGF1R (0.60) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 | |
| Hydrochloric Acid SCHEMBL8576435 | 0.71 | IGF1R (0.65) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL4609182 | 0.71 | SIGMAR1 (0.62) | MAPTALDH1A1SMN1; SMN2MAPK1HTR1A | |
| SCHEMBL11460456 | 0.70 | IGF1R (0.70) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL13875132 | 0.69 | IGF1R (0.65) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 | |
| SCHEMBL4607941 | 0.69 | GRIN2B (0.47) | ALDH1A1 | |
| SCHEMBL8159579 | 0.68 | SIGMAR1 (0.64) | IGF1RMAPTALDH1A1SMN1; SMN2MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | claimed |
| EP-1272187-B1 | DOPAMINE-D3 RECEPTOR LIGANDS FOR THE TREATMENT OF ADDICTION | ABBOTT GMBH & CO KG (DE) | 2008-07-30 | — | — | EP | disclosed |
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087917-A1 | Use of dopamine-d3 receptor ligands for the treatment of diseases of the central nervous system | DRD3, DRD2, OPRD1 | IGF1R 804/4885MAPT 1837/4885ALDH1A1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.